Sunday, January 9, 2011


AVNR was one of the biotechs recommended on this site last year and I thought it would be appropriate to review where we stand on it. This is a stock that one needs to have a core of and trade around the core. It has a new drug approval (Neudexta) for traumatic brain injury condition called Psuedobulbar Affect. This is a condition where the effected individual has uncontrolled or innappropriate laughing or crying responses after brain injury. Roughly 1 million people are effected here by this condition. There are "off label" uses that makes the potential of this drug more difficult to calculate and I will not go into these. This is a followup and a reminder to keep some in your portfolio for diversification.

No comments:

Post a Comment